Thermo Fisher Scientific Cytokeratin, HMW Monoclonal Antibody (34betaE12)

Applications

Tested Dilution

Publications

Immunohistochemistry (Paraffin) (IHC (P))

1:100-1:200

-

Product Specifications

Species Reactivity

Human

Host/Isotype

Mouse / IgG1, kappa

Class

Monoclonal

Type

Antibody

Clone

34betaE12

Immunogen

Solubilized keratin extracted from human stratum corneum if (typeof window.$mangular === undefined || !window.$mangular) { window.$mangular = {}; } $mangular.antigenJson = \[{targetFamily:Cytokeratin HMW,uniProtId:P02533-1,ncbiNodeId:9606,antigenRange:1-472,antigenLength:472,antigenImageFileName:Z2019ML_Cytokeratin_HMW_P02533-1_House_mouse.svg,antigenImageFileNamePDP:Z2019ML_Cytokeratin_HMW_P02533-1_House_mouse_PDP.jpeg,sortOrder:1},{targetFamily:Cytokeratin HMW,uniProtId:P04264-1,ncbiNodeId:9606,antigenRange:1-644,antigenLength:644,antigenImageFileName:Z2019ML_Cytokeratin_HMW_P04264-1_House_mouse.svg,antigenImageFileNamePDP:Z2019ML_Cytokeratin_HMW_P04264-1_House_mouse_PDP.jpeg,sortOrder:2},{targetFamily:Cytokeratin HMW,uniProtId:P13645-1,ncbiNodeId:9606,antigenRange:1-584,antigenLength:584,antigenImageFileName:Z2019ML_Cytokeratin_HMW_P13645-1_House_mouse.svg,antigenImageFileNamePDP:Z2019ML_Cytokeratin_HMW_P13645-1_House_mouse_PDP.jpeg,sortOrder:3},{targetFamily:Cytokeratin HMW,uniProtId:P13647-1,ncbiNodeId:9606,antigenRange:1-590,antigenLength:590,antigenImageFileName:Z2019ML_Cytokeratin_HMW_P13647-1_House_mouse.svg,antigenImageFileNamePDP:Z2019ML_Cytokeratin_HMW_P13647-1_House_mouse_PDP.jpeg,sortOrder:4}\]; $mangular.isB2BCMGT = false; $mangular.isEpitopesModalImageMultiSizeEnabled = true;

View immunogen .st0{fill:#FFFFFF;} .st1{fill:#1E8AE7;}

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Liquid

Concentration

200 µg/mL

Purification

Protein A

Storage buffer

tris with BSA, NP-40

Contains

<0.1% sodium azide

Storage conditions

4° C

Shipping conditions

Wet ice

Product Specific Information

A recommended positive control tissue for this product is Prostate, however positive controls are not limited to this tissue type.

The primary antibody is intended for laboratory professional use in the detection of the corresponding protein in formalin-fixed, paraffin-embedded tissue stained in manual qualitative immunohistochemistry (IHC) testing. This antibody is intended to be used after the primary diagnosis of tumor has been made by conventional histopathology using non-immunological histochemical stains.

Cytokeratin 34bE12 antibody recognizes cytokeratin 1, 5, 10, and 14 in the Moll catalog (MW 68 kDa, 58 kDa, 56.5 kDa, and 50 kDa), respectively. Cytokeratin 34bE12 antibody promises to be a specific marker useful in differential identification of squamous carcinomas from adenocarcinomas and differential diagnosis of benign and malignant tumors of prostatic gland. In normal cells, it labels squamous, ductal and other complex epithelia. It reacts with benign small-acinar lesions of the prostate and does not react with hepatocytes, pancreatic acinar cells, proximal renal tubes or endometrial glands. In tumor cells, this antibody is reactive with both squamous and ductal neoplasms and variably with those derived from simple epithelium.

Antibody is used with formalin-fixed and paraffin-embedded sections. Pretreatment of deparaffinized tissue with heat-induced epitope retrieval or enzymatic retrieval is recommended. In general, immunohistochemical (IHC) staining techniques allow for the visualization of antigens via the sequential application of a specific antibody to the antigen (primary antibody), a secondary antibody to the primary antibody (link antibody), an enzyme complex and a chromogenic substrate with interposed washing steps. The enzymatic activation of the chromogen results in a visible reaction product at the antigen site. Results are interpreted using a light microscope and aid in the differential diagnosis of pathophysiological processes, which may or may not be associated with a particular antigen.

A positive tissue control must be run with every staining procedure performed. This tissue may contain both positive and negative staining cells or tissue components and serve as both the positive and negative control tissue. External Positive control materials should be fresh autopsy/biopsy/surgical specimens fixed, processed and embedded as soon as possible in the same manner as the patient sample (s). Positive tissue controls are indicative of correctly prepared tissues and proper staining methods. The tissues used for the external positive control materials should be selected from the patient specimens with well-characterized low levels of the positive target activity that gives weak positive staining. The low level of positivity for external positive controls is designed to ensure detection of subtle changes in the primary antibody sensitivity from instability or problems with the staining methodology. A tissue with weak positive staining is more suitable for optimal quality control and for detecting minor levels of reagent degradation.

Internal or external negative control tissue may be used depending on the guidelines and policies that govern the organization to which the end user belongs to. The variety of cell types present in many tissue sections offers internal negative control sites, but this should be verified by the user. The components that do not stain should demonstrate the absence of specific staining, and provide an indication of non-specific background staining. If specific staining occurs in the negative tissue control sites, results with the patient specimens must be considered invalid.

Target Information

Keratins are heteropolymeric structural proteins that form the intermediate filament. Cytokeratins are intermediate filament keratins found in the intracytoplasmic cytoskeleton of epithelial tissue. There are two types of cytokeratins - the low weight, acidic type I and the high weight, basic type II. Cytokeratins are usually found in pairs - one type I and one type II. KRT1 regulates the activity of kinases such as PKC and SRC via binding to integrin beta-1 (ITB1) and the receptor of activated protein C kinase I (RACK1). In complex with C1QBP it is a high affinity receptor for kininogen-1/HMWK. KRT1 is expressed in the spinous and granular layers of the epidermis with family member KRT10. Mutations affecting the gene result in bullous congenital ichthyosiform erythroderma. KRT5 is specifically expressed in the basal layer of the epidermis with family member KRT14. Mutations affecting the gene result in epidermolysis bullosa simplex diseases. KRT10 plays a role in the establishment of the epidermal barrier on plantar skin. It also acts as a mediator of S.aureus adherence to desquamated nasal epithelial cells via clfB - thus it plays a role in nasal colonization. Mutations affecting the gene result in epidermolytic hyperkeratosis. KRT14`s nonhelical tail domain is involved in promoting KRT5-KRT14 filaments to self-organize into large bundles and enhances the mechanical properties involved in resilience of keratin intermediate filaments in vitro. Mutations affecting the gene result in epidermolysis bullosa simplex.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.